cardiology
Medicines

PCSK9 inhibitors have their place but come at a cost: CSANZ 2018

PCSK9 inhibitors make a lot of biological sense and there is data to support their use in lowering LDL cholesterol; we just have to figure out if we can afford them. Speaking ahead of a CSANZ 2018 session on hyperlipidaemia, Professor Len Kritharides said the challenge was finding the people in whom PCSK9 inhibition becomes ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic